Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ju Fu Tang Biotech Holdings Co (HKSE:08217) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ju Fu Tang Biotech Holdings Co ROE % Related Terms
Ju Fu Tang Biotech Holdings Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Engineering & Construction subindustry, Ju Fu Tang Biotech Holdings Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ju Fu Tang Biotech Holdings Co ROE % vs Construction Industry
For the Construction industry and Industrials sector, Ju Fu Tang Biotech Holdings Co's ROE % distribution charts can be found below:
* The bar in red indicates where Ju Fu Tang Biotech Holdings Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ju Fu Tang Biotech Holdings Co (HKSE:08217) has a ROE % of 7.58% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. According to the industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #49 out of 1750 companies in the Construction industry, placing it in the top 2.8%.
Is Ju Fu Tang Biotech Holdings Co's ROE % too high?
Ju Fu Tang Biotech Holdings Co's current ROE % is 7.58%. The Construction industry median ROE % is 6.72. Ju Fu Tang Biotech Holdings Co's value of 7.58% is 12.9% above this industry median. Based on the distribution chart, Ju Fu Tang Biotech Holdings Co ranks #49 out of 1750 companies in the Construction industry, which is in the top quartile — a strong position relative to peers. Overall, Ju Fu Tang Biotech Holdings Co has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ju Fu Tang Biotech Holdings Co's ROE % compare to PWR and FIX?
According to the Construction industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #49 out of 1750 companies for ROE %. This places Ju Fu Tang Biotech Holdings Co in the top 3% of its industry — outperforming the majority of peers. The industry median ROE % is 6.72. Ju Fu Tang Biotech Holdings Co's value of 7.58% is 12.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Construction company?
The median ROE % among Construction companies is 6.72, based on 1,750 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ju Fu Tang Biotech Holdings Co's current ROE % of 7.58% is 12.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. For the Construction industry, the median ROE % is 6.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ju Fu Tang Biotech Holdings Co's current ROE % is 7.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ju Fu Tang Biotech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co (HKSE:08217) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.11 — trading 28.7% below its estimated fair value. The current ROE % is 7.58% and 12.9% above the Construction industry median of 6.72. Ju Fu Tang Biotech Holdings Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ju Fu Tang Biotech Holdings Co (HKSE:08217), the current ROE % is 7.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ju Fu Tang Biotech Holdings Co (HKSE:08217) Overvalued in 2026?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 28.7% below its estimated GF Value™ of HK$0.15.
GuruFocus considers Ju Fu Tang Biotech Holdings Co to be Modestly Undervalued.
Key valuation signals for HKSE:08217:
ROE %: 7.58%
GF Value™: HK$0.15 vs. price of HK$0.11 (28.7% below fair value)
Industry Position: 12.9% above the Construction median (#49 of 1750)
No single metric tells the full story. See the HKSE:08217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ju Fu Tang Biotech Holdings Co Ltd, formerly known as WMHW Holdings Ltd, is an investment holding company operating through its subsidiaries. It engaged in the provision of construction works and investment holding.
36GF Score
Get the complete analysis for HKSE:08217
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08217 has been successfully added to your 
